Phase II study of carboplatin and gemcitabine chemotherapy in patients with advanced ovarian cancer resistant or refractory to previous platinum chemotherapy.

Trial Profile

Phase II study of carboplatin and gemcitabine chemotherapy in patients with advanced ovarian cancer resistant or refractory to previous platinum chemotherapy.

Completed
Phase of Trial: Phase II

Latest Information Update: 17 Jun 2016

At a glance

  • Drugs Carboplatin; Gemcitabine
  • Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Therapeutic Use
  • Sponsors Eli Lilly
  • Most Recent Events

    • 10 Aug 2012 Accrual to date is 102% according to United Kingdom Clinical Research Network.
    • 17 Aug 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 12 Nov 2009 Status changed from completed to active, no longer recruiting as reported by United Kingdom Clinical Research Network.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top